Furthermore, compounds 42–49 circumvented P-gp-mediated drug resistance, as confirmed by cytotoxicity assays in NCI/ADR-RES ovarian cancer cells, which overexpressed P-gp. This evidence concerns the gene PGP and ovarian carcinoma.